Myeloid-derived suppressor cells in cancer patients: A clinical perspective

Alberto J. Montero, Claudia Marcela Diaz-Montero, Christos E. Kyriakopoulos, Vincenzo Bronte, Susanna Mandruzzato

Research output: Contribution to journalArticlepeer-review


Myeloid-derived suppressor cells (MDSCs) represent a heterogenous collection of immature myeloid cells endowed with suppressive function on the immune response. Their presence has been extensively investigated in preclinical models, especially in the context of cancer. One of the major obstacles in their accurate identification has been the definition of an unambiguous phenotype, shared between mice and humans, and clearly correlating with their suppressive function. In this paper, we review the literature concerning the phenotype in mouse and in humans, showing that at least 2 subsets of MDSCs are present under different situations. We also address the role of MDSCs in tumor progression, evaluate the prognostic significance of MDSC in cancer patients, and their possible role as marker of clinical outcome and response to therapy. Finally, we examine the strategies designed to modulate MDSCs in cancer patients, which might represent an innovative approach to enhance the effectiveness of immune-based therapies.

Original languageEnglish
Pages (from-to)107-115
Number of pages9
JournalJournal of Immunotherapy
Issue number2
Publication statusPublished - Feb 2012


  • myeloid cells
  • myeloid-derived suppressor cells
  • suppression

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology


Dive into the research topics of 'Myeloid-derived suppressor cells in cancer patients: A clinical perspective'. Together they form a unique fingerprint.

Cite this